louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03702595: Effects of a Stretching Protocol in Patients With Hip Osteoarthritis
Official title: Effects of a Stretching Protocol of Hip Flexors in Patients With Mild to Moderate Hip Osteoarthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hip Osteoarthritis
Keywords: Hip Osteoarthritis
Manual therapy
physiotherapy
Lead sponsor: Universidad de Zaragoza
Sponsor class: OTHER
Collaborators: name: University of Valladolid
First posted: 2018-10-11
Enrollment: 15
Sex: ALL
Minimum age (years): 50
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Hip osteoarthritis (OA) is one of the most prevalent chronic disease in the world. Clinical guidelines recommend non-pharmacological conservative treatments for the management of OA. Hip flexors seems to play an important role in the development of hip OA but there is no published studies evaluating the results of a stretching protocol of hip flexors in hip OA patients.

The objective of this trial is to evaluate if a stretching protocol of hip flexors is more effective in symptoms, functional capacity , range of motion, strength, muscular length, pain threshold and anxiety and depression compared to control.

For this purpose the investigators conduct a single-group, pretest-posttest clinical trial.The investigators included patients diagnosed of hip osteoarthritis Grade I-III by Scale of Kellgren and Lawrence.

The variables are measured at the beginning and at the end of treatment of the control phase, and at the end of the stretching protocol phase.


Eligibility criteria: Inclusion Criteria:

* Diagnosed medically with a X-Ray test
* American College of Rheumatology Criteria

Exclusion Criteria:

* Secondary osteoarthritis by a traumatism, Paget disease, inflammatory or metabolic disease, congenital diseases etc.
* Vascular or neurological disease.
* Musculoskeletal pathologies in lumbar spine, pelvis or lower limbs
* Grade IV in Kellgren and Laurence Scale

Primary outcomes:
measure: Changes from baseline in pain intensity
timeFrame: 3 weeks
Secondary outcomes:
measure: Functional Capacity
timeFrame: 3 weeks
measure: WOMAC questionnaire
timeFrame: 3 weeks
measure: Hip Range of Motion
timeFrame: 3 weeks
measure: Muscular strength
timeFrame: 3 weeks
measure: Muscular length
timeFrame: 3 weeks
measure: Pressure Pain threshold
timeFrame: 3 weeks
measure: Anxiety and Depression
timeFrame: 3 weeks
Other outcomes:
Locations:
city: Soria
country: Spain
facility: Sandra Jiménez del Barrio
city: Zaragoza
country: Spain
facility: Luis Ceballos Laita
Study officials:
References:
Clinical trial NCT01348295: Pediatric Ventilatory Care in Finland 2010
Official title: Pediatric Ventilatory Care in Finland 2010
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Mechanical Ventilation
Children
Neonates
Pediatric Intensive Care
Keywords: Mechanical ventilation
Children
Neonates
Pediatric intensive care
Lead sponsor: University of Oulu
Sponsor class: OTHER
First posted: 2011-05-05
Enrollment: 210
Sex: ALL
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All children under 16 years needing mechanical ventilation in Finland from 13th of September 2010 to 19th of December 2010.

Brief summary: This observational study includes questionnaires send to doctors in all units treating pediatric patients with mechanical ventilation in Finland. Additionally all units treating pediatric patients with mechanical ventilation are invited to perform a quality control-like follow up for 3 months. Patient identity data is not collected, and no interventions to treatment are made.


Eligibility criteria: Inclusion Criteria:

* Age under 16 years
* Mechanical ventilation during the follow up period

Primary outcomes:
measure: The duration of mechanical ventilation
timeFrame: 1-2000 hours
Secondary outcomes:
measure: Ventilator parameters
timeFrame: 1-2000hours
Other outcomes:
Locations:
city: Oulu
country: Finland
facility: University Hospital of Oulu
state: Pohjois-Pohjanmaa
Study officials:
References:
Clinical trial NCT00643695: Efficacy of an Exercise Intervention to Decrease Depressive Symptoms in Veterans With Hepatitis C
Official title: Efficacy of an Exercise Intervention to Decrease Depressive Symptoms in Veterans With Hepatitis C
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hepatitis C
Depression
Keywords: hepatitis C
depression
exercise
Lead sponsor: Portland VA Medical Center
Sponsor class: FED
First posted: 2008-03-26
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this study, depressed veterans with hepatitis C will be randomly assigned to the control group or to the exercise intervention group. The exercise intervention is designed to begin slowly for most participants and to progress within each participant's target heart rate range for moderate intensity exercise. The exercise intervention is a 12 week home based walking program. Ideally individuals will walk for 30 minutes, at a moderate intensity, a minimum of three times per week. However, the duration and relative intensity will be tailored for each individual.

Central Hypothesis Veterans who receive the exercise intervention will be significantly less symptomatic for depression than veterans in the control group.


Eligibility criteria: Inclusion Criteria:

* Male or female, age 18 or older
* Documentation of positive hepatitis C status as indicated by a detectable HCV viral load by polymerase chain reaction
* Mild to moderate depressive symptoms as evidenced by a BDI II score of ≥ 14
* Able to read and understand English
* Written/signed informed consent specific to this protocol
* Being sedentary that is , less than 30 minutes of planned low to moderate intensity exercise 2 days per week

Exclusion Criteria:

* Suicidal ideations
* Current interferon therapy or planning to begin interferon therapy during the next three months
* Diagnosis of Bipolar disorder, Schizophrenia, or Post Traumatic Stress Disorder
* Any medical condition, disorder, or medication that contraindicates participation in a mild to moderate intensity walking program

Primary outcomes:
measure: Reduction of symptoms of depression as measured by the Beck Depression Inventory II (BDI-II)
timeFrame: 12 weeks
Secondary outcomes:
measure: Reduction in symptoms of fatigue as measured by the Brief Fatigue Inventory (BFI)
timeFrame: 12 weeks
measure: reduce the reported level of chronic pain
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Portland
country: United States
facility: Portland VA Medical Center
state: Oregon
Study officials:
affiliation: Portland VA Medical Center
name: Patricia Taylor-Young, PhD, RN,FNP
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04975295: A Study of LY3361237 in Participants With Psoriasis
Official title: A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3361237 in Participants With Psoriasis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Psoriasis
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
First posted: 2021-07-23
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The main purpose of this study is to learn more about the safety and tolerability of LY3361237 and any side effects that might be associated with it when given to participants with psoriasis. LY3361237 will be administered by injections just under the skin. The study will last up to 41 weeks and may include up to 15 visits to the study center.


Eligibility criteria: Inclusion Criteria:

* Have chronic plaque psoriasis for at least 6 months
* Be willing and able to undergo skin biopsies
* Body mass index (BMI) within the range of 18 to 40 kilograms per meter squared (kg/m²)
* Female participants must agree to use birth control during the study

Exclusion Criteria:

* Have had certain types of infection within the last six months
* Have a clinically significant active infection, or recent acute active infection within the last 30 days
* Have other serious or unstable illnesses
* Have a history of organ or bone marrow transplant
* Have received any live vaccine within the last 4 weeks prior to screening
* Have received systemic nonbiologic psoriasis therapy within 4 weeks prior to study day 1
* Have received topical psoriasis treatment within 14 days prior to study day 1
* Have excessive skin exposure or use tanning booths for at least 4 weeks prior to study day 1

Primary outcomes:
measure: Number of Participants with One or More Treatment-Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
timeFrame: Baseline through Day 253
Secondary outcomes:
measure: Pharmacokinetics (PK): Minimum Serum Concentration (Cmin) of LY3361237 During the Dosing Interval
timeFrame: Day 1 predose through Day 253
Other outcomes:
Locations:
city: Sofia
country: Bulgaria
facility: MC Comac Medical
city: Budapest
country: Hungary
facility: Budai Irgalmasrendi Korhaz
city: Lodz
country: Poland
facility: All Med - Lodz
city: Poznan
country: Poland
facility: Ai Centrum Medyczne Sp. Z O.O. Sp.K.
city: Warszawa
country: Poland
facility: WIP Warsaw IBD Point Profesor Kierkus
city: Warszawa
country: Poland
facility: Pratia - Warsaw
city: Bratislava
country: Slovakia
facility: Summit Clinical Research, s.r.o. - Bratislava
Study officials:
affiliation: Eli Lilly and Company
name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
role: STUDY_DIRECTOR
References:
Clinical trial NCT05972395: Conditioned Pain Modulation in Localized vs Widespread Chronic Low Back Pain
Official title: Determining if Conditioned Pain Modulation Differs Between Individuals With Localized Versus Widespread Mechanical Pain Hypersensitivity in Chronic Low Back Pain
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Chronic Low-back Pain
Lead sponsor: Ahram Canadian University
Sponsor class: OTHER
First posted: 2023-08-02
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults with chronic nonspecific LBP stratified by localized vs widespread mechanical hyperalgesia

Brief summary: This study aims to compare function of the body's endogenous pain modulation system between people with localized low back pain versus widespread body pain. Endogenous pain modulation refers to the body's natural ability to inhibit one pain stimulus by applying a second pain stimulus. This study will assess pain inhibition by measuring pressure pain thresholds at the low back before and during cold water hand immersion. The researchers hypothesize that those with widespread body pain will have worse functioning of pain inhibition compared to those with localized low back pain only. The results may provide insights into personalized chronic pain management approaches.

Detailed description: Chronic low back pain (CLBP) is highly prevalent worldwide. Impairments in conditioned pain modulation (CPM) have been documented in CLBP populations. CPM refers to endogenous pain inhibition, where one noxious stimulus inhibits pain from a second noxious stimulus. This relies on descending inhibitory pathways. However, it is unknown whether CPM alterations differ between individuals with localized versus widespread mechanical pain hypersensitivity. The aim of this cross-sectional quantitative sensory testing study is to compare CPM function between localized and widespread CLBP subgroups. A sample of 75 adults with CLBP of at least 3 months duration will be recruited from a chronic pain clinic. Based on pressure pain threshold mapping at the low back and distal sites, participants will be classified as having localized or widespread mechanical hyperalgesia.

Eligibility criteria: Inclusion Criteria:

* Ages 18-60 years
* Chronic LBP \>3 months
* Average LBP intensity ≥4/10

Exclusion Criteria:

* Known LBP pathologies
* Previous lumbar surgery
* Neuropathic LBP
* Comorbid generalized pain conditions

Primary outcomes:
measure: Conditioned Pain Modulation
timeFrame: Baseline
Secondary outcomes:
measure: Pressure Pain Thresholds
timeFrame: baseline
Other outcomes:
Locations:
city: Al Ḩayy Ath Thāmin
country: Egypt
facility: Outpatient clinic of faculty of physical therapy, Ahram Canadian University
state: Giza
Study officials:
affiliation: Faculty of Physical Therapy, Ahram Canadian University
name: Amal Fawzy, Ph.d
role: STUDY_CHAIR
References:
Clinical trial NCT00992095: Bioequivalency Study of Buprenorphine Hydrochloride 8 mg Tablet Under Fasted Conditions
Official title: A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalency Study of Buprenorphine HCl (Sublingual) 8 mg Tablets With a Naltrexone Block Under Fasting Conditions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Opioid-Related Disorders
Lead sponsor: West-Ward Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2009-10-09
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The objective of this study was to prove the bioequivalence of Buprenorphine HCl 8 mg tablet under fasted conditions.


Eligibility criteria: Inclusion Criteria:

* No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.

Exclusion Criteria:

* Positive test for HIV, Hepatitis B, or Hepatitis C.
* Treatment with known enzyme altering drugs. History of allergic or adverse response to buprenorphine hydrochloride or any comparable or similar product.

Primary outcomes:
measure: bioequivalence determined by statistical comparison Cmax
timeFrame: 21 days
Secondary outcomes:
Other outcomes:
Locations:
city: Austin
country: United States
facility: CEDRA Clinical Research
state: Texas
Study officials:
affiliation: CEDRA Clinical Research
name: Fredrick A. Bieberdorf, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06631495: All-cause and Diseases-specific Mortality of High-risk HPV Infection
Official title: All-cause and Diseases-specific Mortality of High-risk HPV Infection
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: HPV Infection
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2024-10-08
Enrollment: 100000
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Female participate in cervical cancer screening

Brief summary: The corresponding prevention strategies and treatment routes of HPV infection can be provided through investigating causes of death due to HPV infection and specialized diseases.

Detailed description: Anxiety and panic about HPV infection have become common phenomena in tumor screening. Transitional and useless diagnosis and treatment caused by HPV infection are also common, affecting women's physical and mental health and health economic level. If the investigators can understand the causes of death related to HPV infection and specialized diseases, the investigators can provide corresponding prevention strategies and treatment routes from the level of health policies and individual methods and mechanisms, and also alleviate the related panic caused by HPV infection.

Eligibility criteria: Inclusion Criteria:

1. Female participate in at least once cervical cancer screening with clear information of HPV DNA test results;
2. Having clear identification (ID number or others) that can be retrieved in the cause of death database.

Exclusion Criteria:

Cases that do not fully meet all inclusion criteria are used as exclusion criteria.

Primary outcomes:
measure: HR-HPV infection AND all-cause and diseases-specific mortality
timeFrame: one year
Secondary outcomes:
measure: time-period of HR-HPV infection AND all-cause and diseases-specific mortality
timeFrame: one year
measure: HR-HPV type AND all-cause and diseases-specific mortality
timeFrame: one year
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking Union Medical College Hospital
Study officials:
References:
Clinical trial NCT03966495: Sustainability of a Research Program in Risk Management (PeRENNITe)
Official title: Sustainability of a Research Program in Risk Management: Routine Implementation, Appropriation, Effectiveness, Development of the Safety Culture
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: RM Program
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2019-05-29
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pluriprofessional primary care offices in France (called "centre, pôle et maison de santé pluridisciplinaire")

Brief summary: Sustainability can be defined by several dimensions: the pursuit of program elements, the maintenance of its effectiveness, its integration into work processes, the adaptation of the program to the local context, its integration into the organizational culture, the dissemination of the program to other centres. Studies show that the continuation of the entire intervention is rare once the research stops.

The PRisM study (Pluriprofessionality and Risk Management through a Multifaceted Program in Primary Care) was a primary care risk management (RM) research project. Its purpose was to develop a safety culture within the participating multi-professional primary care structures. From 2015 to 2017, multi-professional primary care offices participated in the study, half of which implemented a RM program consisting of: 1) Training on RM in the context of primary care; 2) The appointment of a RM referent; 3) The conduct of six meetings of systematic analysis of incidents.

The PRisM study represents a favorable ground for the development of a methodology for evaluating the sustainability of a RM program in primary care.


Eligibility criteria: Inclusion Criteria:

* Volontary pluriprofessional primary care offices
* Having participated in the PRiSM study

Exclusion Criteria:

* office that waived participation in the PRisM study course
* office with a participation rate in the first PRisM safety climate survey \< 30%.
* office of the PRisM study intervention group that did not implement the program as planned

Primary outcomes:
measure: patient safety culture
timeFrame: 24 months from the end of the PRiSM study in 2017 (2019)
measure: patient safety culture
timeFrame: 24 months from the end of the PRiSM study in 2017 (2019)
Secondary outcomes:
Other outcomes:
Locations:
city: Lyon
country: France
facility: Pôle de Santé publique des HCL
Study officials:
affiliation: Hospices Civils de Lyon
name: Pauline OCCELLI, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02875795: Carcinologic Speech Severity Index
Official title: A Speech Disorders Severity Index to Measure the Impact of Oral and Pharyngeal Cavity on Speech Production
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Head and Neck Cancer
Keywords: linguistic
quality of life
Lead sponsor: University Hospital, Toulouse
Sponsor class: OTHER
Collaborators: name: University Jean-Jaures, Toulouse, France
First posted: 2016-08-23
Enrollment: 124
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The hypothesis of the present study is that an automatic assessment technic can measure the impact of the speech disorders on the communication abilities giving a severity index of speech in patients treated for head and neck and particularly for oral and pharyngeal cancer.


Eligibility criteria: Inclusion Criteria:

* Oral and Pharyngeal cancer T2 to T4 for having a wide dynamic of deficit
* Treatment by surgery and/or radiotherapy and/or chemotherapy
* Delay after the end of the treatment of minimum 6 months.

Exclusion Criteria:

* Patients with a previous speech disorders (ie stuttering... )
* Patients not able to perform the whole task

Primary outcomes:
measure: carcinologic speech severity index
timeFrame: day 0
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: woisard.v@chu-toulouse.fr
name: Virginie WOISARD, Md
role: PRINCIPAL_INVESTIGATOR
References:
citation: Balaguer M, Boisguerin A, Galtier A, Gaillard N, Puech M, Woisard V. Assessment of impairment of intelligibility and of speech signal after oral cavity and oropharynx cancer. Eur Ann Otorhinolaryngol Head Neck Dis. 2019 Oct;136(5):355-359. doi: 10.1016/j.anorl.2019.05.012. Epub 2019 Jun 6.